$1.18
-0.02 (-1.67%)
Open$1.23
Previous Close$1.20
Day High$1.26
Day Low$1.18
52W High$3.19
52W Low$0.87
Volume—
Avg Volume799.9K
Market Cap76.04M
P/E Ratio—
EPS$-0.64
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,763.6% upside
Current
$1.18
$1.18
Target
$21.99
$21.99
$18.66
$21.99 avg
$31.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 31.19M | 31.61M | 26.89M |
| Net Income | 2.24M | 2.16M | 1.99M |
| Profit Margin | 7.2% | 6.8% | 7.4% |
| EBITDA | 3.54M | 3.42M | 2.98M |
| Free Cash Flow | 1.72M | 2.00M | 2.13M |
| Rev Growth | -3.9% | +21.8% | -6.2% |
| Debt/Equity | 0.32 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |